<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">3 Biotech</journal-id><journal-id journal-id-type="iso-abbrev">3 Biotech</journal-id><journal-title-group><journal-title>3 Biotech</journal-title></journal-title-group><issn pub-type="ppub">2190-572X</issn><issn pub-type="epub">2190-5738</issn><publisher><publisher-name>Springer Berlin Heidelberg</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28330086</article-id><article-id pub-id-type="pmc">4705057</article-id><article-id pub-id-type="publisher-id">334</article-id><article-id pub-id-type="doi">10.1007/s13205-015-0334-1</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Cloning, expression, purification and characterization of human mitochondrial carbonic anhydrase VA</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Idrees</surname><given-names>Danish</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kumar</surname><given-names>Sudhir</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Rehman</surname><given-names>Syed Abdul Arif</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Gourinath</surname><given-names>Samudrala</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Islam</surname><given-names>Asimul</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ahmad</surname><given-names>Faizan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Imtaiyaz Hassan</surname><given-names>Md.</given-names></name><address><phone>+91-11-2698-3409</phone><email>mihassan@jmi.ac.in</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label>Centre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, Jamia Nagar, New Delhi, 110025 India </aff><aff id="Aff2"><label>2</label>School of Life Sciences, Jawaharlal Nehru University, New Delhi, 110025 India </aff></contrib-group><pub-date pub-type="epub"><day>7</day><month>1</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>7</day><month>1</month><year>2016</year></pub-date><pub-date pub-type="ppub"><month>6</month><year>2016</year></pub-date><volume>6</volume><issue>1</issue><elocation-id>16</elocation-id><history><date date-type="received"><day>17</day><month>4</month><year>2015</year></date><date date-type="accepted"><day>23</day><month>6</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2016</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p></license></permissions><abstract id="Abs1"><p>Carbonic anhydrase VA (CAVA) is a mitochondrial enzyme that catalyzes the reversible hydration of CO<sub>2</sub> to produce HCO<sub>3</sub>
<sup>&#x02212;</sup> and proton. CAV is primarily involved in several biosynthetic processes such as ureagenesis, gluconeogenesis and lipogenesis by providing bicarbonate ion. Here, we report a new strategy for cloning, expression and purification for CAVA in the bacterial system followed by its biophysical characterization. The cDNA of CAVA, a 801 nucleotide long that encodes a 267-amino acid polypeptide of molecular mass of 30-kDa (excluding signal peptide), was sub-cloned in the expression vector pET21c and transformed into <italic>Escherichia coli</italic> strain BL21 (DE3) for expression. The recombinant protein was purified in two steps by Ni&#x02013;NTA and DEAE weak anion-exchange chromatography under native condition from the supernatant, while inclusion bodies (IBs) were used to get protein under the denatured condition with a relatively high yield. CAVA was purified under denatured conditions in a single step using Ni&#x02013;NTA chromatography. SDS-PAGE showed a band of 30-kDa, which was further confirmed as CAVA by Western blot and MALDI-TOF/MS. We further performed enzyme activity to ensure that both forms of purified proteins are enzymatically active. Measurements of secondary structure of the native, denatured and renatured proteins were carried out using circular dichroism. The purified protein can be further used for structural and biochemical studies.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Carbonic anhydrase VA</kwd><kwd>Protein expression</kwd><kwd>Gluconeogenesis</kwd><kwd>Enzyme assay</kwd><kwd>Circular dichroism</kwd><kwd>Protein purification</kwd></kwd-group><funding-group><award-group><funding-source><institution>DST FIST</institution></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; King Abdulaziz City for Science and Technology 2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p>Carbonic anhydrase V (CAV) is a mitochondrial enzyme (Dodgson et al. <xref ref-type="bibr" rid="CR5">1980</xref>) that catalyzes the hydration of carbon dioxide to produce proton and bicarbonate. CAV exists in two closely related mitochondrial isoform known as carbonic anhydrase VA (CAVA) and CAVB which have a distinct tissue distribution (Imtaiyaz Hassan et al. <xref ref-type="bibr" rid="CR13">2013</xref>). CAVB is expressed in the heart, skeletal muscle, kidney, salivary gland and spinal cord (Ghandour et al. <xref ref-type="bibr" rid="CR6">2000</xref>), while CAVA is localized in the mitochondria and expressed primarily in the liver (Saarnio et al. <xref ref-type="bibr" rid="CR23">1999</xref>). CAVA is actively involved in several biosynthetic processes such as ureagenesis, gluconeogenesis and lipogenesis and helps in glucose (Dodgson and Cherian <xref ref-type="bibr" rid="CR4">1989</xref>; Parkkila et al. <xref ref-type="bibr" rid="CR20">1998</xref>), fatty acid and urea synthesis (van Karnebeek et al. <xref ref-type="bibr" rid="CR27">2014</xref>). CAV is the only mammalian CA which is compartmentalized in a cell organelle and it has tyrosine at 64<sup>th</sup> position instead of histidine, a catalytic proton shuttle residue which transfers proton from zinc-bound water to buffer (Boriack-Sjodin et al. <xref ref-type="bibr" rid="CR2">1995</xref>; Vitale et al. <xref ref-type="bibr" rid="CR28">2007</xref>). However, the proton shuttle transport in CAV is still not clear.</p><p>CAVA gene was localized to chromosome 16q24.3 and an unprocessed pseudogene has been assigned to 16p12 (Nagao et al. <xref ref-type="bibr" rid="CR19">1995</xref>). CAVA gene is composed of 915 nucleotides encoding a 305-amino acid protein with a molecular mass of 35-kDa. It has a hydrophobic N-terminal mitochondrial signal sequence of 38 amino acid residues and a catalytic domain of 267-amino acids. Based on the effect of CA inhibitors on these processes, a physiological role of CAVA in the biosynthetic processes has been suggested (Liang et al. <xref ref-type="bibr" rid="CR17">1993</xref>; Heck et al. <xref ref-type="bibr" rid="CR11">1994</xref>). In fact, mitochondria require CAV for these metabolic processes, and deregulation of this enzyme causes obesity (Arechederra et al. <xref ref-type="bibr" rid="CR1">2013</xref>), which is one of the most common human diseases, because of alteration in the metabolic substrate flux (Picard et al. <xref ref-type="bibr" rid="CR22">2000</xref>). Inhibition of CAVA has been identified as a novel anti-obesity strategy, over the other because of their serious cardiovascular or central nervous system (CNS) side effects. Several studies have provided insight that inhibition of CAVA with sulfonamide/sulfamate drug has potential as anti-obesity (Kaul and Ritschel <xref ref-type="bibr" rid="CR16">1988</xref>). However, better inhibitors are needed to overcome the problem of selectivity, since CAVA share a close homology, with other CA isoform, to design selective inhibitors of CAVA is challenging (Iqbal et al. <xref ref-type="bibr" rid="CR14">2015</xref>; Swenson <xref ref-type="bibr" rid="CR26">2014</xref>).</p><p>We tried to express the full length of CAVA in the bacterial system, but protein was unable to get solubilized. To overcome this problem, we have sub-cloned cDNA of CAVA into expression vector pET21c, encoding a 267-amino acid protein corresponding to the catalytic domain only (801 nucleotides and 30-kDa). Moreover, we have purified CAVA from both soluble supernatant and inclusion bodies (IBs). We further optimized the purification procedure to get the soluble proteins from inclusion bodies which have similar structure and enzyme activity in comparison to the protein purified from the supernatant. The aim of the present study is to construct a prokaryotic expression system for producing recombinant protein which can be used for structure&#x02013;function studies in future.</p></sec><sec id="Sec2"><title>Materials and methods</title><sec id="Sec3"><title>Strains and plasmid</title><p>Clone of CAVA was purchased from PlasmID Harvard Medical School. DH5&#x003b1; and BL21 (DE3) strains of <italic>E. coli</italic> were used for cloning and expression of the protein, respectively. <italic>E. coli</italic> cells harboring recombinant plasmid were grown aerobically at 37&#x000a0;&#x000b0;C in Luria&#x02013;Bertani (Merck, Darmstadt, Germany) broth with 100&#x000a0;&#x003bc;g/ml ampicillin (Sigma, Saint Louis, MO, USA). Plasmid pET-21c (Novagen, WI, USA) was used as expression vector. Plasmid isolation, restriction enzyme digestion, ligation and competent cell preparation were carried out using standard procedure.</p></sec><sec id="Sec4"><title>Cloning of CAVA gene</title><p>The 801-bp coding region (39-305aa) was amplified by PCR from plasmid pENTR2231 containing the CAVA gene using forward and reverse primers 5&#x02032;CTAGCTAGCTGTGCATGGCAAACCAGCAA3&#x02032; and 5&#x02032;CGGCTCGAGTAAGGACCTTTGCCCTCATTAG3&#x02032;, respectively. This amplification generated <italic>Nhe1</italic> and <italic>Xho1</italic> sites on each end of the amplified fragment and excluded the coding region (1-38aa) for the putative signal sequence. The CAVA gene was sub-cloned into pET21c vector with the C-terminal His6 tag.</p></sec><sec id="Sec5"><title>Expression of recombinant protein CAVA</title><p>The constructed expression vector (pET21c-CAVA) containing coding region of CAVA gene was transformed into <italic>E. coli</italic> BL21 (DE3) host cells by following the standard protocol. Overnight culture of the expression cells from a freshly transformed plate was inoculated in LB media, containing 100&#x000a0;&#x003bc;g/&#x000b5;l ampicillin, and incubated at 37&#x000a0;&#x000b0;C, with constant agitation at 220&#x000a0;rpm in an incubator shaker until the absorbance reaches 0.6 at 600&#x000a0;nm. The culture was induced by 0.50&#x000a0;mM IPTG (Sigma, Saint Louis, USA) and incubated for next 15&#x000a0;h at 16&#x000a0;&#x000b0;C. Cells were centrifuged at 7000<italic>g</italic> for 10&#x000a0;min at 4&#x000a0;&#x000b0;C. Then, cells were dissolved in 50&#x000a0;mM Tris&#x02013;HCl buffer, pH 8.0 containing 500&#x000a0;mM NaCl, 5&#x000a0;% (v/v) glycerol, 5&#x000a0;mM &#x003b2;-mercaptoethanol, 0.1&#x000a0;mg/ml lysozyme, 100&#x000a0;mM phenyl methane sulfonyl fluoride (PMSF) and 1&#x000a0;% (v/v) triton X-100 (U. S. Biochemical Corp). Cell lysate was sonicated on ice and centrifuged for 30&#x000a0;min at 13,000&#x000a0;rpm at 4&#x000a0;&#x000b0;C. Supernatant was collected for purification of CAVA by the nickel affinity chromatography.</p></sec><sec id="Sec6"><title>Purification of CAVA under native condition</title><p>A clear supernatant was passed through Ni&#x02013;NTA column which was pre-equilibrated with a buffer (50&#x000a0;mM Tris&#x02013;HCl, pH 8.0, 500&#x000a0;mM NaCl, 5&#x000a0;% (v/v glycerol, 5&#x000a0;mM &#x003b2;-mercaptoethanol, 10&#x000a0;mM imidazole). After binding of protein, column was washed with 50&#x000a0;ml of washing buffer (50&#x000a0;mM Tris&#x02013;HCl, pH 8.0, 500&#x000a0;mM NaCl, 5&#x000a0;% (v/v) glycerol, 5&#x000a0;mM &#x003b2;-mercaptoethanol, 20&#x000a0;mM imidazole) at 4&#x000a0;&#x000b0;C. Bound protein was eluted with 300&#x000a0;mM imidazole. The fractions were concentrated using Amicon Ultra 10&#x000a0;K device (Merck Darmstadt, Germany) and dialyzed against 50&#x000a0;mM Tris&#x02013;HCl pH 8.0 buffer. The dialyzed sample was further loaded on Hi Trap DEAE FF (1&#x000a0;ml, 7&#x000a0;mm&#x000a0;&#x000d7;&#x000a0;25&#x000a0;mm) column (GE healthcare) pre-equilibrated with 50&#x000a0;mM Tris&#x02013;HCl buffer, pH 8.0. Bound proteins were eluted with increasing concentration of NaCl (0&#x02013;1&#x000a0;M NaCl) in the 50&#x000a0;mM Tris&#x02013;HCl pH 8.0 buffer. Elution was controlled by Akta purifier (GE healthcare) with a flow rate of 0.5&#x000a0;ml/min. CAVA eluted at 0.50&#x000a0;M NaCl was pooled, concentrated and stored for further study. The purity of protein was confirmed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).</p></sec><sec id="Sec7"><title>Alternative methods of CAVA purification</title><p>We also report an alternative method of CAVA purification as a major portion of CAVA which was expressed as insoluble protein in the form of inclusion bodies (IBs). Earlier, we successfully purified the protein from the soluble form, but its yield was very low. To increase the yield of CAVA protein, we have tried a number of different methods to isolate the protein from IBs.</p></sec><sec id="Sec8"><title>Preparation and solubilization of IBs</title><p>
<italic>Escherichia coli</italic> cells were centrifuged, pellets were resuspended in lysis buffer (50&#x000a0;mM phosphate buffer and 300&#x000a0;mM NaCl, pH 7.0) and lysed through sonicate, and IBs in the cell lysate were pelleted by low-speed centrifugation. Then, the pellet was again resuspended and washed with milli-Q water through centrifugation thrice to remove contaminations and got purified IBs. Solubilization of IBs is a vital step to obtaining the maximal amount of desired protein. We tried various denaturing conditions, such as urea, 1&#x000a0;% SDS, guanidinium chloride (GdmCl) and 1&#x000a0;% <italic>N</italic>-lauroylsarcosine to obtain maximum amount of our protein. CAVA was solubilized in all conditions. We solubilized the purified IBs with 50&#x000a0;mM phosphate buffer pH 7.0, 300&#x000a0;mM NaCl and 1&#x000a0;% <italic>N</italic>-lauroylsarcosine, and incubated on rocker for 30&#x000a0;min. We centrifuged the solubilized IBs for 30&#x000a0;min at 12,000&#x000a0;rpm and collected the supernatant.</p></sec><sec id="Sec9"><title>Purification of recombinant CAVA from IBs</title><p>Ni&#x02013;NTA column was equilibrated with equilibration buffer (50&#x000a0;mM phosphate buffer pH 7.0, 50&#x000a0;mM NaCl and 1&#x000a0;% <italic>N</italic>-lauroylsarcosine). The collected supernatant was loaded on equilibrated Ni&#x02013;NTA column. Then, the column was washed with washing buffer (50&#x000a0;mM phosphate buffer pH 7.0, 50&#x000a0;mM NaCl and 1&#x000a0;% <italic>N</italic>-lauroylsarcosine and 20&#x000a0;mM imidazole). The desired protein was eluted with elution buffer (50&#x000a0;mM phosphate buffer pH 7.0, 50&#x000a0;mM NaCl and 0.5&#x000a0;% <italic>N</italic>-lauroylsarcosine and 300&#x000a0;mM imidazole). The fractions of eluted CAVA protein were collected and checked for homogeneity on SDS-PAGE.</p></sec><sec id="Sec10"><title>Western blotting</title><p>Band of CAVA protein on SDS-PAGE was transferred onto the nitrocellulose membrane using standard procedure. Nitrocellulose membrane was blocked with 5&#x000a0;% non-fatty acid milk powder in phosphate-buffered saline (PBS) for 2&#x000a0;h followed by three washing. Conjugate Anti-His&#x02013;HRP antibody (Penta-His, Qiagen) was incubated with the membranes for another 2&#x000a0;h and subsequently washed to remove the unbound antibody. Blot was developed by incubating the membrane for 2&#x000a0;min with 3, 30-diaminobenzidine (DAB) reagents (Zhongshan Biotech, Beijing) and 200&#x000a0;&#x003bc;l hydrogen peroxide.</p></sec><sec id="Sec11"><title>Mass spectrometry</title><p>To know the amino acid sequence of purified protein, we performed matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-ToF/MS). The band of CAVA from the SDS-PAGE was excised for tryptic digestion and subjected to mass spectrometer (Kratos Analytical, Shimadzu Group Company, Japan). We used standard procedure for the sequencing of CAVA, which was described elsewhere in detail (Hassan et al. <xref ref-type="bibr" rid="CR7">2007a</xref>, <xref ref-type="bibr" rid="CR10">2008</xref>). The peptide mass finger prints were used to identify protein by searching the SWISS-PROT and NCBI-nr databases using the Mascot 2.0 search engine with fragment mass tolerance of &#x000b1;0.5&#x000a0;Da and max missed cleavages of one (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>).<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>List of peptide fragments obtained after trypsinization</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Start&#x02013;end</th><th align="left">Observed</th><th align="left">Nominal mass (expected)</th><th align="left">Nominal mass (calculated)</th><th align="left">ppm</th><th align="left">Peptide</th></tr></thead><tbody><tr><td align="left">38&#x02013;63</td><td char="." align="char">2865.4580</td><td char="." align="char">2864.4507</td><td char="." align="char">2864.4028</td><td char="." align="char">17</td><td align="left">R. SCAWQTSNNTLHPLWT</td></tr><tr><td align="left">64&#x02013;72</td><td char="." align="char">1141.6107</td><td char="." align="char">1140.6034</td><td char="." align="char">1140.6040</td><td char="." align="char">&#x02212;0</td><td align="left">R.QSPINIQWR.D</td></tr><tr><td align="left">73&#x02013;84</td><td char="." align="char">1430.7755</td><td char="." align="char">1430.7755</td><td char="." align="char">1429.7682</td><td char="." align="char">8</td><td align="left">R.DSVYDPQLKPLR.V</td></tr><tr><td align="left">169&#x02013;185</td><td char="." align="char">1715.0111</td><td char="." align="char">1714.0038</td><td char="." align="char">1713.9665</td><td char="." align="char">22</td><td align="left">K.EAVVGENGLAVIGVFLK</td></tr><tr><td align="left">186&#x02013;195</td><td char="." align="char">1160.6216</td><td char="." align="char">1159.6143</td><td char="." align="char">1159.6210</td><td char="." align="char">&#x02212;6</td><td align="left">K.LGAHHQTLQR.L</td></tr><tr><td align="left">250&#x02013;263</td><td char="." align="char">1529.8103</td><td char="." align="char">1528.8030</td><td char="." align="char">1528.7885</td><td char="." align="char">9</td><td align="left">K.EPVEVAPSQLSAFR.T</td></tr><tr><td align="left">276&#x02013;290</td><td char="." align="char">1876.9592</td><td char="." align="char">1875.9519</td><td char="." align="char">1875.9270</td><td char="." align="char">13</td><td align="left">K.MMVNNYRPLQPLMNR</td></tr><tr><td align="left">291&#x02013;304</td><td char="." align="char">1594.8141</td><td char="." align="char">1593.8068</td><td char="." align="char">1593.7899</td><td char="." align="char">11</td><td align="left">R.KVWASFQATNEGTR.S</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec12"><title>Enzyme activity</title><p>To confirm the active nature of the purified protein, we performed enzyme activity of the native and renatured CAVA molecules. The <italic>p</italic>-nitrophenyl acetate (NPA) was used as the substrate to measure the activity of CAVA by recording the increase of absorbance at 400&#x000a0;nm (Ikai et al. <xref ref-type="bibr" rid="CR12">1978</xref>). The reaction cuvette contained 0.1&#x000a0;mM <italic>p</italic>-nitrophenyl acetate in 50&#x000a0;mM Tris pH 8.0, 5&#x000a0;% acetonitrile and enzyme in the concentration of 0.3&#x000a0;mg/ml for both CAII and CAVA at 25&#x000a0;&#x000b0;C. We have taken CAII as a positive control for activity. Esterase activity was carried out by following the release of nitrophenol which was measured at 400&#x000a0;nm by spectrophotometer (Jasco V-660, Model B 028661152) equipped with Peltier-type temperature controller (ETCS-761). All spectral measurements were done at least three times at 25&#x000a0;&#x000b1;&#x000a0;0.1&#x000a0;&#x000b0;C.</p></sec><sec id="Sec13"><title>Circular dichroism</title><p>Secondary structure of CAVA was measured using circular dichroism (CD) in Jasco spectropolarimeter (model J-1500) equipped with Peltier type temperature controller. The far-UV CD spectra (250&#x02013;200&#x000a0;nm) were recorded at 25&#x000a0;&#x000b1;&#x000a0;0.1&#x000a0;&#x000b0;C using a cuvette of 1&#x000a0;mm path length cell and protein concentration of 0.3&#x000a0;mg/ml (10&#x000a0;&#x003bc;M). Samples of the native and renatured CAVA were prepared in 50&#x000a0;mM Tris&#x02013;HCl and 50&#x000a0;mM phosphate buffer containing 150&#x000a0;mM NaCl at pH 8.0 and 7.0, respectively. Denatured sample was prepared in phosphate buffer with 1&#x000a0;% <italic>N</italic>-lauroylsarcosine at pH 7.0. The raw CD data were converted to the mean residue ellipticity, [<italic>&#x003b8;</italic>] (degrees cm<sup>2</sup> dmol<sup>&#x02212;1</sup>), using the relation:<disp-formula id="Equ1"><label>1</label><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$[ {\theta = {\text{Mo}}} [\theta ]/10lc$$\end{document}</tex-math><mml:math id="M2" display="block"><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mrow><mml:mi mathvariant="italic">&#x003b8;</mml:mi><mml:mo>=</mml:mo><mml:mtext>Mo</mml:mtext></mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mi mathvariant="italic">&#x003b8;</mml:mi><mml:mo stretchy="false">]</mml:mo><mml:mo stretchy="false">/</mml:mo><mml:mn>10</mml:mn><mml:mi>l</mml:mi><mml:mi>c</mml:mi></mml:mrow></mml:math><graphic xlink:href="13205_2015_334_Article_Equ1.gif" position="anchor"/></alternatives></disp-formula>where [<italic>&#x003b8;</italic>] is the observed ellipticity in millidegrees, Mo is the mean residue weight of the protein, <italic>c</italic> is the concentration in mg/ml, and <italic>l</italic> is the path length of the cell in centimetre. The CD spectra were uploaded onto the K2D2 server to estimate the secondary structural content of CAVA (Perez-Iratxeta and Andrade-Navarro <xref ref-type="bibr" rid="CR21">2008</xref>). This server is based on the comparison of real and predicted values, by means of the Pearson correlation coefficient (<italic>r</italic>) and the root mean square deviation (RMSD) of proteins with known three-dimensional structure. A detail of algorithm is described elsewhere (Johnson <xref ref-type="bibr" rid="CR15">1999</xref>; McPhie <xref ref-type="bibr" rid="CR18">2008</xref>; Sreerama and Woody <xref ref-type="bibr" rid="CR25">2000</xref>).</p></sec></sec><sec id="Sec14"><title>Results</title><sec id="Sec15"><title>Cloning and expression of CAVA</title><p>The CAVA gene from plasmid pENTR223 was amplified by PCR, with <italic>Nhe1</italic> and <italic>Xho1</italic> site at the 5&#x02032; and 3&#x02032; end, respectively. The amplified product was 801&#x000a0;bp long (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>a). It was digested with same restriction enzymes <italic>Nhe1</italic> and <italic>Xho1</italic>, and subsequently ligated to the pET21c <italic>Nhe1</italic> and <italic>Xho1</italic> backbone fragment. This clone was confirmed by colony PCR (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>b) and restriction digestion with <italic>Nhe1</italic> and <italic>Xho1</italic> endonucleases (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>c). Constructed plasmid was further verified by DNA sequencing (not shown). The confirmed plasmid constructed pET21c-CAVA was transformed into <italic>E. coli</italic> BL21 (DE3). Recombinant protein was expressed at 16&#x000a0;&#x000b0;C by inducing with 0.5&#x000a0;mM IPTG. Overexpression of CAVA was clearly indicated on SDS-PAGE with an apparent molecular weight of 30-kDa (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>a).<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Cloning of CAVA gene: <bold>a</bold> amplified CAVA gene.<italic> Lane 1</italic>: Marker and <italic>Lane 2</italic> is an amplified product of 801&#x000a0;bp. <bold>b</bold> Confirmed constructed plasmid by colony PCR.<italic> Lane 1</italic> is a marker and lanes 3 to 8 are amplified products, further confirmed by restriction digestion. <bold>c</bold> Digested products back bone of 5.4&#x000a0;kb of pET21c and gene of CAVA of 801 nucleotides (<italic>Lane 2</italic>) and<italic> Lane 1</italic> is a marker</p></caption><graphic xlink:href="13205_2015_334_Fig1_HTML" id="MO2"/></fig>
<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Purification of CAVA under native condition. <bold>a</bold> SDS-PAGE showing the expression of recombinant CAVA protein. <bold>b</bold> SDS-PAGE showing an eluent obtained from Ni&#x02013;NTA column chromatography.<italic> Lane 1</italic> is flow through,<italic> lane 2</italic> is washing with 20&#x000a0;mM imidazole and<italic> lanes 3 to 9</italic> are eluent fractions. <bold>c</bold> Elution profile of ion-exchange chromatography. <bold>d</bold> SDS-PAGE of purified CAVA.<italic> Lane 1</italic> is a molecular mass marker and<italic> lane 2</italic> shows purified CAVA</p></caption><graphic xlink:href="13205_2015_334_Fig2_HTML" id="MO3"/></fig>
</p></sec><sec id="Sec16"><title>Purification of CAVA under native condition</title><p>To purify proteins in biologically active form from bacterial system, require an optimization of expression, solubilization of IBs and refolding experiments. Here, we expressed CAVA in <italic>E</italic>. coli BL21 (DE3). The major portion of the protein was expressed as insoluble fractions. Hence, we have purified CAVA successfully under the native as well as denatured conditions. The recombinant CAVA protein was isolated and purified to homogeneity at 4&#x000a0;&#x000b0;C from cell extract under the native condition. CAVA was found in the soluble bacterial extract, and obtained after the centrifugation of sonicated <italic>E. coli</italic> cell at 20,000<italic>g</italic>. CAVA was purified to homogeneity by two chromatographic steps on Ni&#x02013;NTA affinity chromatography and DEAE ion-exchange chromatography. The eluted fractions after Ni&#x02013;NTA affinity chromatography showed a significant level of contamination by other proteins (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>b). Eluted fractions were pooled, extensively dialyzed and loaded on to the DEAE anion exchanger column to get pure CAVA. Elution profile of DEAE anion exchanger column chromatography is shown in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>c. Fractions of protein obtained in DEAE anion exchanger column were subjected to SDS-PAGE to check the purity. A clear single band was observed on SDS-PAGE indicating the purity of CAVA (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>d). A summary of CAVA purification procedure is provided in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>.<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Purification summary</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">S. no.</th><th align="left">Purification step</th><th align="left">Volume (ml)</th><th align="left">Protein (mg/ml)<sup>b</sup>
</th><th align="left">Total protein (mg)</th><th align="left">Yield (100&#x000a0;%)</th></tr></thead><tbody><tr><td align="left">1</td><td align="left">
<italic>E. coli</italic> cell pellet<sup>a</sup>
</td><td char="." align="char">60</td><td char="." align="char">43.91</td><td char="." align="char">2635.02</td><td align="left">100</td></tr><tr><td align="left">2</td><td align="left">Supernatant</td><td char="." align="char">56</td><td char="." align="char">1.428</td><td char="." align="char">79.968</td><td align="left">3.034</td></tr><tr><td align="left">3</td><td align="left">Ni-affinity chromatography</td><td char="." align="char">15</td><td char="." align="char">0.136</td><td char="." align="char">2.04</td><td align="left">0.077</td></tr><tr><td align="left">4</td><td align="left">Weak anion chromatography (DEAE column)</td><td char="." align="char">2</td><td char="." align="char">0.504</td><td char="." align="char">1.008</td><td align="left">0.038</td></tr></tbody></table><table-wrap-foot><p>
<sup>a</sup>From 8&#x000a0;g of wet weight <italic>E. coli</italic> cell pellet (from 4 litre of batch)</p><p>
<sup>b</sup>Protein concentration determined by Lowry assay using BSA as a standard protein</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec17"><title>Purification of CAVA under denatured condition</title><p>To improve protein yield, we purified CAVA protein under denatured condition from IBs because large portion of recombinant CAVA protein was expressed there. We isolated IBs from cell extract and purified by sequential washing with milli-Q water to remove contaminants, especially non-specific proteins and proteases. Purified IBs of 30 kDa were checked on SDS-PAGE (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>a). We used 1&#x000a0;% <italic>N</italic>-lauroylsarcosine to solubilize the IBs among other denaturants because of problems in downstream processes. Solubilized IBs were loaded on an Ni&#x02013;NTA affinity chromatography and purified in single chromatography step. The purity and yield of fractions of purified CAVA were checked on SDS-PAGE (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>b).<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Purification of CAVA under denatured condition. <bold>a</bold> SDS-PAGE showing expression of CAVA in IBs.<italic> Lane 1</italic> shows a marker and<italic> lane 2</italic> is for CAVA, <bold>b</bold> SDS-PAGE shows an eluent obtained from Ni&#x02013;NTA column chromatography (<italic>lanes 1&#x02013;4 </italic> and <italic>6</italic>) and<italic> lane 5</italic> is marker (prestained protein marker, broad range (7&#x02013;175&#x000a0;kDa)</p></caption><graphic xlink:href="13205_2015_334_Fig3_HTML" id="MO4"/></fig>
</p></sec><sec id="Sec18"><title>Refolding of CAVA</title><p>Refolding of the protein is an important process to remove excess denaturants and provide appropriate condition for protein to spontaneously refold into correct conformation. There is no standard protocol for refolding of proteins. We refolded CAVA by dialyzing the solution against 50&#x000a0;mM phosphate buffer pH 7.0 and 150&#x000a0;mM NaCl for 24&#x000a0;h at 4&#x000a0;&#x000b0;C. Dialyzed protein was centrifuged to remove any precipitate formed during refolding. To further check that refolded protein is enzymatically active, we performed an enzyme assay. CAVA catalyzes the hydrolysis of <italic>p</italic>-nitrophenyl-acetate to <italic>p</italic>-nitrophenol, measured by recording the increase in absorbance with time. A significant increase in the optical density of solution at 400&#x000a0;nm clearly suggests that purified native and renatured CAVA is enzymatically active (data not shown).</p></sec><sec id="Sec19"><title>Sequencing and identification</title><p>The CAVA was confirmed by Western blot (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>a) and mass spectrometry MALDI-TOF (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>b). Mass spectrometry analysis identified many fragments of CAVA, clearly indicating this protein as human mitochondrial CAVA (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Both these studies clearly indicate that purified protein is CAVA.<fig id="Fig4"><label>Fig.&#x000a0;4</label><caption><p>
<bold>a</bold> Western blot analysis confirmed the presence of recombinant CAVA protein. <bold>b</bold> Peptide mass fingerprint of CAVA</p></caption><graphic xlink:href="13205_2015_334_Fig4_HTML" id="MO5"/></fig>
</p></sec><sec id="Sec20"><title>Secondary structure measurement</title><p>To estimate secondary structure contents, we performed the far-UV CD of denatured, renatured and native CAVA proteins at 25&#x000a0;&#x000b0;C in the region of 250 to 200&#x000a0;nm (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>). Spectra were analyzed to determine the secondary structure content of the protein with available programme (Perez-Iratxeta and Andrade-Navarro <xref ref-type="bibr" rid="CR21">2008</xref>). We used K2D2 server and found the secondary structural contents of the native CAVA as 20.2&#x000a0;% &#x003b1;-helix, 29.1&#x000a0;% &#x003b2;-sheet and 50.7&#x000a0;% random coil, for the renatured CAVA as 21.7&#x000a0;% &#x003b1;-helix, 27.2&#x000a0;% &#x003b2;-sheet and 51.3&#x000a0;% random coil, and for the denatured CAVA contents as 15.3&#x000a0;% &#x003b1;- helix, 21.7&#x000a0;% &#x003b2;-sheet and 63&#x000a0;% random coil. The crystal structure of human CAVA is not determined so far. However, we calculated the secondary structure content through secondary structure prediction server and homology modeling and a considerable correlation was observed between the theoretical calculation of secondary structure and calculation of the CD data. Moreover, refolding study clearly indicates that CAVA is a reversibly denatured protein.<fig id="Fig5"><label>Fig.&#x000a0;5</label><caption><p>Far-UV CD spectra of recombinant protein CAVA. <italic>Curves 1</italic>, <italic>2</italic> and <italic>3</italic> represent spectra of denatured, renatured and native proteins, respectively</p></caption><graphic xlink:href="13205_2015_334_Fig5_HTML" id="MO6"/></fig>
</p></sec></sec><sec id="Sec21"><title>Discussion</title><p>We have successfully cloned, expressed and purified human CAVA (CAVA), which lacks the first 38 amino acid N-terminal residues for putative mitochondrial signal sequence. This is the first report of human CAVA protein purified in the bacterial system in both native and denatured conditions. However, mouse mitochondrial CAVB was successfully expressed and purified from bacterial system, but truncated form of CAVB (CAVB) could not be purified from the bacterial system due to its toxicity for host (Heck et al. <xref ref-type="bibr" rid="CR11">1994</xref>). We compared human CAVA with mouse CAVB, because it has 85&#x000a0;% homology and will try to find out the reason why truncated form of human CAVA is not toxic. We purified CAVA using the combination of Ni&#x02013;NTA affinity and anion exchange chromatography used to purify recombinant protein yielded a pure and homogeneous protein but yield is very low under native conditions. We also used alternate methods to improve yield, prepared IBs and isolated CAVA from it under denaturing conditions. We successfully solubilized IBs using 1&#x000a0;% <italic>N</italic>-lauroylsarcosine, purified through Ni&#x02013;NTA chromatography only, single step purification and refolded into biologically active form. Our yield has been improved, and it is around 40&#x000a0;mg/litre. We identified and confirmed the purified protein by Western bolting as well as MALDI-ToF mass spectrometry. The expression and purification procedures reported in this study have provided a simple and efficient method to obtain pure CAVA protein used for further studies of its structure and function.</p><p>We have successfully cloned, expressed and purified CAVA protein in <italic>E. coli</italic>. We found that purified CAVA from their IBs under denatured condition is a good approach as we got high purity and concentration in single step. We are working on structure-based drug design (Hassan et al. <xref ref-type="bibr" rid="CR7">2007a</xref>, <xref ref-type="bibr" rid="CR8">b</xref>, <xref ref-type="bibr" rid="CR9">c</xref>; Shahbaaz et al. <xref ref-type="bibr" rid="CR24">2015</xref>) and discovery and CAVA is considered as a potential drug target, and some of its inhibitors may lead to the development of novel anti-obesity therapies (Arechederra et al. <xref ref-type="bibr" rid="CR1">2013</xref>; De Simone and Supuran <xref ref-type="bibr" rid="CR3">2007</xref>). Furthermore, structure analysis with docking and MD simulation will further guide to design a potent and selective inhibitor of CAV which will be validated experimentally.</p></sec></body><back><ack><p>We sincerely thank the Department of Science and Technology, Government of India for FIST support. DI thanks University Grants Commission, Government of India for the award of Maulana Azad National Fellowship. The authors declare no conflict of interest. We thank Harvard PlasmID Database for providing the clone of CAVA.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arechederra</surname><given-names>RL</given-names></name><name><surname>Waheed</surname><given-names>A</given-names></name><name><surname>Sly</surname><given-names>WS</given-names></name><name><surname>Supuran</surname><given-names>CT</given-names></name><name><surname>Minteer</surname><given-names>SD</given-names></name></person-group><article-title>Effect of sulfonamides as carbonic anhydrase VA and VB inhibitors on mitochondrial metabolic energy conversion</article-title><source>Bioorg Med Chem</source><year>2013</year><volume>21</volume><issue>6</issue><fpage>1544</fpage><lpage>1548</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2012.06.053</pub-id><pub-id pub-id-type="pmid">22854196</pub-id></element-citation></ref><ref id="CR2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boriack-Sjodin</surname><given-names>PA</given-names></name><name><surname>Heck</surname><given-names>RW</given-names></name><name><surname>Laipis</surname><given-names>PJ</given-names></name><name><surname>Silverman</surname><given-names>DN</given-names></name><name><surname>Christianson</surname><given-names>DW</given-names></name></person-group><article-title>Structure determination of murine mitochondrial carbonic anhydrase V at 2.45-A resolution: implications for catalytic proton transfer and inhibitor design</article-title><source>Proc Natl Acad Sci USA</source><year>1995</year><volume>92</volume><issue>24</issue><fpage>10949</fpage><lpage>10953</lpage><pub-id pub-id-type="doi">10.1073/pnas.92.24.10949</pub-id><pub-id pub-id-type="pmid">7479916</pub-id></element-citation></ref><ref id="CR3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Simone</surname><given-names>G</given-names></name><name><surname>Supuran</surname><given-names>CT</given-names></name></person-group><article-title>Antiobesity carbonic anhydrase inhibitors</article-title><source>Curr Top Med Chem</source><year>2007</year><volume>7</volume><issue>9</issue><fpage>879</fpage><lpage>884</lpage><pub-id pub-id-type="doi">10.2174/156802607780636762</pub-id><pub-id pub-id-type="pmid">17504132</pub-id></element-citation></ref><ref id="CR4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dodgson</surname><given-names>SJ</given-names></name><name><surname>Cherian</surname><given-names>K</given-names></name></person-group><article-title>Mitochondrial carbonic anhydrase is involved in rat renal glucose synthesis</article-title><source>Am J Physiol</source><year>1989</year><volume>257</volume><issue>6 Pt 1</issue><fpage>E791</fpage><lpage>E796</lpage><pub-id pub-id-type="pmid">2514597</pub-id></element-citation></ref><ref id="CR5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dodgson</surname><given-names>SJ</given-names></name><name><surname>Forster</surname><given-names>RE</given-names><suffix>2nd</suffix></name><name><surname>Storey</surname><given-names>BT</given-names></name><name><surname>Mela</surname><given-names>L</given-names></name></person-group><article-title>Mitochondrial carbonic anhydrase</article-title><source>Proc Natl Acad Sci U S A</source><year>1980</year><volume>77</volume><issue>9</issue><fpage>5562</fpage><lpage>5566</lpage><pub-id pub-id-type="doi">10.1073/pnas.77.9.5562</pub-id><pub-id pub-id-type="pmid">6776540</pub-id></element-citation></ref><ref id="CR6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghandour</surname><given-names>MS</given-names></name><name><surname>Parkkila</surname><given-names>AK</given-names></name><name><surname>Parkkila</surname><given-names>S</given-names></name><name><surname>Waheed</surname><given-names>A</given-names></name><name><surname>Sly</surname><given-names>WS</given-names></name></person-group><article-title>Mitochondrial carbonic anhydrase in the nervous system: expression in neuronal and glial cells</article-title><source>J Neurochem</source><year>2000</year><volume>75</volume><issue>5</issue><fpage>2212</fpage><lpage>2220</lpage><pub-id pub-id-type="doi">10.1046/j.1471-4159.2000.0752212.x</pub-id><pub-id pub-id-type="pmid">11032910</pub-id></element-citation></ref><ref id="CR7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hassan</surname><given-names>MI</given-names></name><name><surname>Kumar</surname><given-names>V</given-names></name><name><surname>Kashav</surname><given-names>T</given-names></name><name><surname>Alam</surname><given-names>N</given-names></name><name><surname>Singh</surname><given-names>TP</given-names></name><name><surname>Yadav</surname><given-names>S</given-names></name></person-group><article-title>Proteomic approach for purification of seminal plasma proteins involved in tumor proliferation</article-title><source>J Sep Sci</source><year>2007</year><volume>30</volume><issue>12</issue><fpage>1979</fpage><lpage>1988</lpage><pub-id pub-id-type="doi">10.1002/jssc.200700028</pub-id><pub-id pub-id-type="pmid">17638362</pub-id></element-citation></ref><ref id="CR8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hassan</surname><given-names>MI</given-names></name><name><surname>Kumar</surname><given-names>V</given-names></name><name><surname>Singh</surname><given-names>TP</given-names></name><name><surname>Yadav</surname><given-names>S</given-names></name></person-group><article-title>Structural model of human PSA: a target for prostate cancer therapy</article-title><source>Chem Biol Drug Des</source><year>2007</year><volume>70</volume><issue>3</issue><fpage>261</fpage><lpage>267</lpage><pub-id pub-id-type="doi">10.1111/j.1747-0285.2007.00553.x</pub-id><pub-id pub-id-type="pmid">17718721</pub-id></element-citation></ref><ref id="CR9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hassan</surname><given-names>MI</given-names></name><name><surname>Kumar</surname><given-names>V</given-names></name><name><surname>Somvanshi</surname><given-names>RK</given-names></name><name><surname>Dey</surname><given-names>S</given-names></name><name><surname>Singh</surname><given-names>TP</given-names></name><name><surname>Yadav</surname><given-names>S</given-names></name></person-group><article-title>Structure-guided design of peptidic ligand for human prostate specific antigen</article-title><source>J Pept Sci</source><year>2007</year><volume>13</volume><issue>12</issue><fpage>849</fpage><lpage>855</lpage><pub-id pub-id-type="doi">10.1002/psc.911</pub-id><pub-id pub-id-type="pmid">17890654</pub-id></element-citation></ref><ref id="CR10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hassan</surname><given-names>MI</given-names></name><name><surname>Kumar</surname><given-names>V</given-names></name><name><surname>Singh</surname><given-names>TP</given-names></name><name><surname>Yadav</surname><given-names>S</given-names></name></person-group><article-title>Purification and characterization of zinc alpha2-glycoprotein-prolactin inducible protein complex from human seminal plasma</article-title><source>J Sep Sci</source><year>2008</year><volume>31</volume><issue>12</issue><fpage>2318</fpage><lpage>2324</lpage><pub-id pub-id-type="doi">10.1002/jssc.200700686</pub-id><pub-id pub-id-type="pmid">18563756</pub-id></element-citation></ref><ref id="CR11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heck</surname><given-names>RW</given-names></name><name><surname>Tanhauser</surname><given-names>SM</given-names></name><name><surname>Manda</surname><given-names>R</given-names></name><name><surname>Tu</surname><given-names>C</given-names></name><name><surname>Laipis</surname><given-names>PJ</given-names></name><name><surname>Silverman</surname><given-names>DN</given-names></name></person-group><article-title>Catalytic properties of mouse carbonic anhydrase V</article-title><source>J Biol Chem</source><year>1994</year><volume>269</volume><issue>40</issue><fpage>24742</fpage><lpage>24746</lpage><pub-id pub-id-type="pmid">7929150</pub-id></element-citation></ref><ref id="CR12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ikai</surname><given-names>A</given-names></name><name><surname>Tanaka</surname><given-names>S</given-names></name><name><surname>Noda</surname><given-names>H</given-names></name></person-group><article-title>Reactivation of kinetics of guanidine denatured bovine carbonic anhydrase B</article-title><source>Arch Biochem Biophys</source><year>1978</year><volume>190</volume><issue>1</issue><fpage>39</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1016/0003-9861(78)90251-5</pub-id><pub-id pub-id-type="pmid">101152</pub-id></element-citation></ref><ref id="CR13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imtaiyaz Hassan</surname><given-names>M</given-names></name><name><surname>Shajee</surname><given-names>B</given-names></name><name><surname>Waheed</surname><given-names>A</given-names></name><name><surname>Ahmad</surname><given-names>F</given-names></name><name><surname>Sly</surname><given-names>WS</given-names></name></person-group><article-title>Structure, function and applications of carbonic anhydrase isozymes</article-title><source>Bioorg Med Chem</source><year>2013</year><volume>21</volume><issue>6</issue><fpage>1570</fpage><lpage>1582</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2012.04.044</pub-id><pub-id pub-id-type="pmid">22607884</pub-id></element-citation></ref><ref id="CR14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iqbal</surname><given-names>J</given-names></name><name><surname>Al-Rashida</surname><given-names>M</given-names></name><name><surname>Durdagi</surname><given-names>S</given-names></name><name><surname>Alterio</surname><given-names>V</given-names></name><name><surname>Di Fiore</surname><given-names>A</given-names></name></person-group><article-title>Recent developments of carbonic anhydrase inhibitors as potential drugs</article-title><source>Biomed Res Int</source><year>2015</year><volume>2015</volume><fpage>174178</fpage><pub-id pub-id-type="pmid">25821785</pub-id></element-citation></ref><ref id="CR15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>WC</given-names></name></person-group><article-title>Analyzing protein circular dichroism spectra for accurate secondary structures</article-title><source>Proteins</source><year>1999</year><volume>35</volume><issue>3</issue><fpage>307</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1097-0134(19990515)35:3&#x0003c;307::AID-PROT4&#x0003e;3.0.CO;2-3</pub-id><pub-id pub-id-type="pmid">10328265</pub-id></element-citation></ref><ref id="CR16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaul</surname><given-names>S</given-names></name><name><surname>Ritschel</surname><given-names>WA</given-names></name></person-group><article-title>Influence of obesity on sulfonamide disposition in Zucker rats</article-title><source>Eur J Drug Metab Pharmacokinet</source><year>1988</year><volume>13</volume><issue>4</issue><fpage>273</fpage><lpage>283</lpage><pub-id pub-id-type="doi">10.1007/BF03190091</pub-id><pub-id pub-id-type="pmid">3243323</pub-id></element-citation></ref><ref id="CR17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>Z</given-names></name><name><surname>Jonsson</surname><given-names>BH</given-names></name><name><surname>Lindskog</surname><given-names>S</given-names></name></person-group><article-title>Proton transfer in the catalytic mechanism of carbonic anhydrase. Effects of placing histidine residues at various positions in the active site of human isoenzyme II</article-title><source>Biochim Biophys Acta</source><year>1993</year><volume>1203</volume><issue>1</issue><fpage>142</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.1016/0167-4838(93)90048-V</pub-id><pub-id pub-id-type="pmid">8218383</pub-id></element-citation></ref><ref id="CR18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McPhie</surname><given-names>P</given-names></name></person-group><article-title>Concentration-independent estimation of protein secondary structure by circular dichroism: a comparison of methods</article-title><source>Anal Biochem</source><year>2008</year><volume>375</volume><issue>2</issue><fpage>379</fpage><lpage>381</lpage><pub-id pub-id-type="doi">10.1016/j.ab.2008.01.024</pub-id><pub-id pub-id-type="pmid">18294952</pub-id></element-citation></ref><ref id="CR19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagao</surname><given-names>Y</given-names></name><name><surname>Batanian</surname><given-names>JR</given-names></name><name><surname>Clemente</surname><given-names>MF</given-names></name><name><surname>Sly</surname><given-names>WS</given-names></name></person-group><article-title>Genomic organization of the human gene (CA5) and pseudogene for mitochondrial carbonic anhydrase V and their localization to chromosomes 16q and 16p</article-title><source>Genomics</source><year>1995</year><volume>28</volume><issue>3</issue><fpage>477</fpage><lpage>484</lpage><pub-id pub-id-type="doi">10.1006/geno.1995.1177</pub-id><pub-id pub-id-type="pmid">7490083</pub-id></element-citation></ref><ref id="CR20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parkkila</surname><given-names>AK</given-names></name><name><surname>Scarim</surname><given-names>AL</given-names></name><name><surname>Parkkila</surname><given-names>S</given-names></name><name><surname>Waheed</surname><given-names>A</given-names></name><name><surname>Corbett</surname><given-names>JA</given-names></name><name><surname>Sly</surname><given-names>WS</given-names></name></person-group><article-title>Expression of carbonic anhydrase V in pancreatic beta cells suggests role for mitochondrial carbonic anhydrase in insulin secretion</article-title><source>J Biol Chem</source><year>1998</year><volume>273</volume><issue>38</issue><fpage>24620</fpage><lpage>24623</lpage><pub-id pub-id-type="doi">10.1074/jbc.273.38.24620</pub-id><pub-id pub-id-type="pmid">9733757</pub-id></element-citation></ref><ref id="CR21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perez-Iratxeta</surname><given-names>C</given-names></name><name><surname>Andrade-Navarro</surname><given-names>MA</given-names></name></person-group><article-title>K2D2: estimation of protein secondary structure from circular dichroism spectra</article-title><source>BMC Struct Biol</source><year>2008</year><volume>8</volume><fpage>25</fpage><pub-id pub-id-type="doi">10.1186/1472-6807-8-25</pub-id><pub-id pub-id-type="pmid">18477405</pub-id></element-citation></ref><ref id="CR22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Picard</surname><given-names>F</given-names></name><name><surname>Deshaies</surname><given-names>Y</given-names></name><name><surname>Lalonde</surname><given-names>J</given-names></name><name><surname>Samson</surname><given-names>P</given-names></name><name><surname>Richard</surname><given-names>D</given-names></name></person-group><article-title>Topiramate reduces energy and fat gains in lean (Fa/?) and obese (fa/fa) Zucker rats</article-title><source>Obes Res</source><year>2000</year><volume>8</volume><issue>9</issue><fpage>656</fpage><lpage>663</lpage><pub-id pub-id-type="doi">10.1038/oby.2000.84</pub-id><pub-id pub-id-type="pmid">11225714</pub-id></element-citation></ref><ref id="CR23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saarnio</surname><given-names>J</given-names></name><name><surname>Parkkila</surname><given-names>S</given-names></name><name><surname>Parkkila</surname><given-names>AK</given-names></name><name><surname>Waheed</surname><given-names>A</given-names></name><name><surname>Karttunen</surname><given-names>T</given-names></name><name><surname>Sly</surname><given-names>WS</given-names></name></person-group><article-title>Cell-specific expression of mitochondrial carbonic anhydrase in the human and rat gastrointestinal tract</article-title><source>J Histochem Cytochem</source><year>1999</year><volume>47</volume><issue>4</issue><fpage>517</fpage><lpage>524</lpage><pub-id pub-id-type="doi">10.1177/002215549904700410</pub-id><pub-id pub-id-type="pmid">10082753</pub-id></element-citation></ref><ref id="CR24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shahbaaz</surname><given-names>M</given-names></name><name><surname>Ahmad</surname><given-names>F</given-names></name><name><surname>Hassan</surname><given-names>MI</given-names></name></person-group><article-title>Structure-based function analysis of putative conserved proteins with isomerase activity from Haemophilus influenzae</article-title><source>3 Biotech</source><year>2015</year><volume>5</volume><issue>5</issue><fpage>741</fpage><lpage>763</lpage><pub-id pub-id-type="doi">10.1007/s13205-014-0274-1</pub-id></element-citation></ref><ref id="CR25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sreerama</surname><given-names>N</given-names></name><name><surname>Woody</surname><given-names>RW</given-names></name></person-group><article-title>Estimation of protein secondary structure from circular dichroism spectra: comparison of CONTIN, SELCON, and CDSSTR methods with an expanded reference set</article-title><source>Anal Biochem</source><year>2000</year><volume>287</volume><issue>2</issue><fpage>252</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1006/abio.2000.4880</pub-id><pub-id pub-id-type="pmid">11112271</pub-id></element-citation></ref><ref id="CR26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swenson</surname><given-names>ER</given-names></name></person-group><article-title>Safety of carbonic anhydrase inhibitors</article-title><source>Expert Opin Drug Saf</source><year>2014</year><volume>13</volume><issue>4</issue><fpage>459</fpage><lpage>472</lpage><pub-id pub-id-type="doi">10.1517/14740338.2014.897328</pub-id><pub-id pub-id-type="pmid">24611470</pub-id></element-citation></ref><ref id="CR27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Karnebeek</surname><given-names>CD</given-names></name><name><surname>Sly</surname><given-names>WS</given-names></name><name><surname>Ross</surname><given-names>CJ</given-names></name><name><surname>Salvarinova</surname><given-names>R</given-names></name><name><surname>Yaplito-Lee</surname><given-names>J</given-names></name><name><surname>Santra</surname><given-names>S</given-names></name><name><surname>Shyr</surname><given-names>C</given-names></name><name><surname>Horvath</surname><given-names>GA</given-names></name><name><surname>Eydoux</surname><given-names>P</given-names></name><name><surname>Lehman</surname><given-names>AM</given-names></name><name><surname>Bernard</surname><given-names>V</given-names></name><name><surname>Newlove</surname><given-names>T</given-names></name><name><surname>Ukpeh</surname><given-names>H</given-names></name><name><surname>Chakrapani</surname><given-names>A</given-names></name><name><surname>Preece</surname><given-names>MA</given-names></name><name><surname>Ball</surname><given-names>S</given-names></name><name><surname>Pitt</surname><given-names>J</given-names></name><name><surname>Vallance</surname><given-names>HD</given-names></name><name><surname>Coulter-Mackie</surname><given-names>M</given-names></name><name><surname>Nguyen</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>LH</given-names></name><name><surname>Bhavsar</surname><given-names>AP</given-names></name><name><surname>Sinclair</surname><given-names>G</given-names></name><name><surname>Waheed</surname><given-names>A</given-names></name><name><surname>Wasserman</surname><given-names>WW</given-names></name><name><surname>Stockler-Ipsiroglu</surname><given-names>S</given-names></name></person-group><article-title>Mitochondrial carbonic anhydrase VA deficiency resulting from CA5A alterations presents with hyperammonemia in early childhood</article-title><source>Am J Hum Genet</source><year>2014</year><volume>94</volume><issue>3</issue><fpage>453</fpage><lpage>461</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2014.01.006</pub-id><pub-id pub-id-type="pmid">24530203</pub-id></element-citation></ref><ref id="CR28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vitale</surname><given-names>RM</given-names></name><name><surname>Pedone</surname><given-names>C</given-names></name><name><surname>Amodeo</surname><given-names>P</given-names></name><name><surname>Antel</surname><given-names>J</given-names></name><name><surname>Wurl</surname><given-names>M</given-names></name><name><surname>Scozzafava</surname><given-names>A</given-names></name><name><surname>Supuran</surname><given-names>CT</given-names></name><name><surname>De Simone</surname><given-names>G</given-names></name></person-group><article-title>Molecular modeling study for the binding of zonisamide and topiramate to the human mitochondrial carbonic anhydrase isoform VA</article-title><source>Bioorg Med Chem</source><year>2007</year><volume>15</volume><issue>12</issue><fpage>4152</fpage><lpage>4158</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2007.03.070</pub-id><pub-id pub-id-type="pmid">17420132</pub-id></element-citation></ref></ref-list></back></article>